BiotechTube
mbiomics

mbiomics

Berlin, Germany· Est.
mbiomics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

mbiomics is a Berlin-based, private biotech developing next-generation microbiome therapeutics for severe chronic diseases. Its core competitive advantage is a proprietary, high-precision fluorescence microscopy-based profiling technology that enables deep, quantitative analysis of microbiome composition to rationally design complex, disease-specific bacterial consortia. The company, which raised €13 million in a Series A round in 2023, is building a therapeutic pipeline and positioning itself at the intersection of advanced analytics and live biotherapeutic product development.

Chronic DiseasesSevere Diseases

Technology Platform

Proprietary fluorescence microscopy-based profiling technology for high-precision, sensitive, and quantitative analysis of in vivo microbiome composition. Uses multiplexing panels to rapidly decipher microbial communities and inform the rational design of complex therapeutic consortia.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The growing recognition of the microbiome's role in chronic diseases creates a large addressable market for effective therapeutics.
The clinical precedent of FMT efficacy validates the approach, while the shift in the field towards complex, rationally designed consortia plays directly to mbiomics' technological strengths.
There is significant potential for strategic partnerships with larger pharma companies seeking expertise in microbiome analysis and drug design.

Risk Factors

The scientific complexity of the microbiome and the translational challenge of moving from analytics to effective, manufacturable drugs present high technical risk.
The company operates in a highly competitive and capital-intensive space with an uncertain regulatory pathway for novel microbial consortia.
As a pre-revenue company, it is dependent on future fundraising, which is contingent on achieving key R&D milestones.

Competitive Landscape

mbiomics competes in the crowded microbiome therapeutics space against well-funded players like Seres Therapeutics, Vedanta Biosciences, and Finch Therapeutics, as well as numerous other private companies and academic spin-outs. Its key differentiator is its proprietary high-resolution analytics platform for consortium design, but it must demonstrate that this technological edge translates into clinically superior products to stand out.

More companies in Microbiome Therapeutics →More companies in Germany →